Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 951 - 1,000 out of 3,730

Document Document Title
WO2004014881B1
The present invention relates to new compounds of formula (I), a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy. In ...  
WO/2004/056789A1
This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-yl­phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPKIERK Kinase ('MEK') enzymes and pharmaceutical compositions and...  
WO/2004/056787A1
The invention relates to NEP inhibitors for treating cardiovascular disorders wherein R1 is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C6alkoxyC,-C3alkyl; R2 is hydrogen or C1-C6alkyl; L is an aromatic heterocyclic ring, optional...  
WO/2004/052280A2
Compounds that inhibit angiogenesis and are useful in the treatment of angiogenic dependent diseases like cancer are disclosed as well as pharmaceutical compositions that contain such compounds, methods of treating angiogenic dependent d...  
WO/2004/052840A1
The invention relates to novel compounds that correspond to the general formula (I) below and to a method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatolog...  
WO/2004/048335A2
The invention is concerned with novel mandelic acid derivatives of formula (I), wherein R1 to R10, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit ...  
WO/2004/048309A1
The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disea...  
WO/2004/048351A2
The invention relates to novel biaromatic compounds that correspond to the general formula (I) below: and to a method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (i...  
WO/2004/046095A1
The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antivira...  
WO/2004/046091A2
The invention relates to novel biaromatic compounds which correspond to the general formula (I), and also to a process for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (i...  
WO/2004/046090A2
This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are...  
WO/2004/043939A1
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...  
WO/2004/043951A1
The present invention relates to compounds, compositions and methods useful for modulating nuclear receptors activity in cells, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, includ...  
WO/2004/041913A1
Highly fluorescent metallo-supramolecules based on terpyridine-based monomers and transition metals have been obtained. These robust supramolecules provide high quantum yields with emissions from violet to blue, green or yellow color. Th...  
WO/2004/037248A2
The present invention relates to compounds, compositions and methods useful for modulating nuclear receptors activity in cells, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, includ...  
WO/2004/035736A2
This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have a...  
WO/2004/033652A2
Improved competitive inhibitors of FAAH employ an &agr -keto heterocyclic pharmacophore and a binding subunit having a ?-unsaturation. The &agr -keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferabl...  
WO/2004/020445A2
Compounds of formula (I) wherein Ao is a bond or a C1-C6alkylene bridge; A1, A2 and A3 are a C1-C6alkylene bridge; D is CH or N; W is, for example, O, S, SO, S02, -C(=O)-O- or -O-C(=O)-; T is a bond or, for example, O, NH, S, SO or SR2; ...  
WO/2004/020393A1
A dibenzylamine compound represented by the general formula (1): (1) (wherein R1 and R2 each is optionally halogenated C1-6 alkyl, etc.; R3, R4, and R5 each is hydrogen, halogeno, etc., provided that R3 and R4 may form an optionally subs...  
WO/2004/018461A2
The present invention relates to antibacterial agents that are useful for sterilization, sanitation, antisepsis, disinfection, and treatment of antibacterial infections in mammals.  
WO/2004/016221A2
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonami...  
WO/2004/014844A2
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists,...  
WO/2004/014357A2
The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Pr...  
WO/2004/015025A1
The present invention relates to polymeric metal complexes comprising metallic complexes covalently bound to conjugated polymers and luminescent materials containing such polymeric metal complexes. The invention further relates to electr...  
WO/2004/014366A1
This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprisi...  
WO/2004/014370A2
The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediat...  
WO/2004/013094A2
One aspect of the present invention relates to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-sulfur bond b...  
WO/2004/009533A1
Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by mo...  
WO/2004/007455A1
The invention relates to heterocyclically substituted benzoylureas, in addition to their physiologically compatible salts and physiologically functional derivatives. The invention relates in particular to compounds of formula (I), in whi...  
WO/2004/005229A1
The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1-R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of an...  
WO/2004/004655A2
Compounds are provided which are useful as antidiabetic agents and antiobesity agents and have the structure (I) wherein m is 0, 1 or 2; n is 0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1 where x1 is 1 to 5 with ...  
WO/2004/003102A2
The invention relates to new polymerizable, luminescent compounds of formula I wherein R1, R2, Q and L1 have the meanings given in claim 1. Furthermore the invention relates to polymerizable mixtures containing compounds according to the...  
WO/2004/002462A2
This invention relates to a method of treating ADHD by administering an alpha2delta ligand such as, for example, gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof.  
WO/2004/002491A1
The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.  
WO/2004/000785A2
A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:  
WO/2004/000797A1
The invention relates to &agr -sulfonylamino-acetonitrile derivatives of the general formula (I) including the optical isomers thereof and mixtures of such isomers, wherein Ar1, and Ar2 independently of each other stand for an optionally...  
WO/2003/105781A2
This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention...  
WO/2003/103660A1
Compounds of Formula I, wherein R1-R8 are defined herein are provided, together with pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these compounds for inhibiting beta amyloid production and fo...  
WO/2003/099776A1
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...  
WO/2003/097617A1
The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is dire...  
WO/2003/097047A1
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I);or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of s...  
WO/2003/097619A1
A novel class of compounds of the general formula (I), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the...  
WO/2003/093248A1
Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.  
WO/2003/090680A2
The present invention related to certain phenyl derivatives that are activators of caspases and inducers of apoptosis, pharmaceutical composition comprising these compounds and method of treating cancer utilizing these compounds.  
WO/2003/087044A2
Novel compounds of formula (I) which modulate MCH activity are disclosed, in which A is a linker; B is a connecting moiety; Ar1 and Ar2 are aryl or heteroaryl groups; R1 and R2 are hydrogen, halogen atoms, CF3, OCF3, SCF3, SCH3, nitrile,...  
WO/2003/087037A1
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of ...  
WO/2003/084915A1
This invention relates to novel compounds according to the general formula : which are thyroid receptor ligands, preferably antagonists, partial antagonists or partial agonists and to methods for using such compounds in the treatment of ...  
WO/2003/084916A2
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods o...  
WO/2003/082861A2
Compounds of formula (I) wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5;R2 represents unsubstituted or subs...  
WO/2003/080038A1
A novel medicinal composition which contains as an active ingredient either a compound represented by the general formula [I] (wherein R1 is hydrogen or optionally substituted alkyl; R2 is dialkylamino, alkyl, cycloalkyl, optionally subs...  

Matches 951 - 1,000 out of 3,730